Baxter International Inc (BAX) Key Developments | Reuters.com
Edition:
United States

Baxter International Inc (BAX)

BAX on New York Consolidated

43.38USD
28 Jun 2016
Change (% chg)

-- (--)
Prev Close
$43.38
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
8,599,992
52-wk High
$46.95
52-wk Low
$32.18

Latest Key Developments (Source: Significant Developments)

Baxter International Inc to cut 1,400 jobs worldwide to boost profits - Reuters
Tuesday, 27 Oct 2015 12:42pm EDT 

Baxter International Inc:Baxter International Inc said on Tuesday it plans to cut about 1,400 jobs worldwide, or about 5 percent of its non-manufacturing workforce, as part of a broad effort to reduce costs and boost profits - RTRS.About two-thirds of the job cuts are planned for outside the United States, with the lay-offs to be completed by the end of the year, Chief Executive Bob Parkinson said on the company's third-quarter earnings call - RTRS.The reduction is expected to save about $130 million a year, he said - RTRS.  Full Article

Baxter International Inc comments on Q4 2015 sales guidance
Tuesday, 27 Oct 2015 06:30am EDT 

Baxter International Inc:Sees Q4 2015 sales to decline 1 percent, excluding the impact of foreign exchange.  Full Article

Baxter International Inc announces U.S. FDA clearance for AMIA automated peritoneal dialysis system
Tuesday, 13 Oct 2015 08:01am EDT 

Baxter International Inc:Says FDA has granted 510(k) clearance for AMIA automated peritoneal dialysis system with SHARESOURCE web-based remote connectivity platform to provide peritoneal dialysis for treatment of end-stage renal disease.Says anticipates launching the Amia APD system with sharesource in the United States in 2015.  Full Article

Baxter International Inc Initiates Voluntary Nationwide Recall Of One Lot Of IV Solution Due To The Potential For Leaking Containers, Particulate Matter And Missing Port - FDA
Wednesday, 29 Jul 2015 08:00pm EDT 

Baxter International Inc:Says it is voluntarily recalling one lot of intravenous (IV) solution to the hospital/user level due to the potential for leaking containers, particulate matter and missing port protectors. Baxter was made aware of these issues through customer complaints - FDA.Says Leaking containers, particulate matter and missing port protectors could result in contamination of the solution.Says If not detected, this could lead to a bloodstream infection or other serious adverse health consequences.Says Injecting a product containing particulate matter, in the absence of in-line filtration, may result in blockage of blood vessels, which can result in stroke, heart attack or damage to other organs such as the kidney or liver.  Full Article

Baxter International Inc declares quarterly dividend
Wednesday, 29 Jul 2015 04:10pm EDT 

Baxter International Inc:Declares a regular quarterly dividend of $0.115 per Baxter common share.This cash dividend is payable on October 1, 2015 to shareholders of record as of September 4, 2015.  Full Article

Baxter International Inc gives Q3, H2 2015 outlook; Q3 2015 EPS outlook above analysts' estimates
Wednesday, 29 Jul 2015 04:05pm EDT 

Baxter International Inc:Expects sales growth of approximately 3 percent in both Q3 2015 and H2 2015.Expects Q3 2015 earnings from continuing operations, before special items, of $0.29 to $0.31 per diluted share and $0.58 to $0.62 per diluted share for H2 2015.Q3 2015 revenue of $2.448 bln and EPS of $0.27 - Thomson Reuters I/B/E/S.  Full Article

Baxter International Inc enters into material definitive agreement - Form 8-K
Thursday, 2 Jul 2015 03:19pm EDT 

Baxter International Inc:Entered into separation and distribution agreement with Baxalta Incorporated.Pursuant to which Baxter agreed to transfer its research-based pharmaceuticals business to Baxalta and about 80.5 pct of outstanding stock of Baxalta to Baxter shareholders in a distribution (the “Distribution”).Distribution was made on July 1, to Baxter shareholders of record as of close of business on June 17.  Full Article

Baxter International Inc prices private placement notes offering
Friday, 19 Jun 2015 08:00am EDT 

Baxter International Inc:Prices $5 billion private placement notes offering.Says priced a private placement offering of $375,000,000 of 2.000 pct senior notes due 2018.Priced a private placement offering of $1 billion of 2.875 pct senior notes due 2020.Priced a private placement offering of $500 million of 3.600 pct senior notes due 2022, $1.75 billion of 4.000 pct senior notes due 2025.  Full Article

Baxter International Inc receives U.S. FDA approval for 0.9 pct sodium chloride injection
Friday, 15 May 2015 05:26pm EDT 

Baxter International Inc:Says U.S. Food and Drug Administration has approved its supplemental drug application to establish Sabinanigo, Spain, facility as an approved manufacturing site for 0.9 pct sodium chloride injection, USP, for U.S. market.Says approval includes product presentations in 250 mL, 500 mL and 1000 mL.  Full Article

Baxter International declares quarterly dividend
Tuesday, 5 May 2015 08:55am EDT 

Baxter International Inc:Declares a quarterly dividend of $0.52 per Baxter common share.Payable on July 1 to shareholders of record as of June 1.  Full Article

BRIEF-Baxter International reports data results from infusion system

* Data shows sigma spectrum infusion system users achieved 97 percent drug library compliance rate within the first month of implementation1 Source text for Eikon: Further company coverage: